住院病房患者电子脓毒症筛查:阶梯楔形整群随机试验
该研究在沙特阿拉伯5家医院45个病房(整群)开展阶梯楔形整群随机试验,2019年10月1日至2021年7月31日期间按9个序列、每2个月将病房随机分配至实施电子脓毒症筛查(基于qSOFA的电子警报,从静默模式转为揭示模式)或不筛查。共纳入60055例患者,筛查组29442例、不筛查组30613例,中位年龄59岁(IQR 39-68),男性30596例(51.0%)。筛查组4299例(14.6%)触发警报、不筛查组5394例(17.6%)触发警报;警报后12小时内筛查组更可能检测血清乳酸(aRR 1.30;95%CI 1.16-1.45)和开具静脉液体(aRR 2.17;95%CI 1.92-2.46)。主要终点90天住院死亡率在筛查组更低(aRR 0.85;95%CI 0.77-0.93;P<.001);筛查减少血管升压药治疗和多药耐药菌,但增加代码蓝色启动、新发肾脏替代治疗和艰难梭菌感染。
要点
- 在5家医院45个病房、60055例住院患者中,电子脓毒症筛查使90天住院死亡率降低(aRR 0.85;95%CI 0.77-0.93;P<.001)。
- 筛查组警报后12小时内血清乳酸检测(aRR 1.30;95%CI 1.16-1.45)和静脉液体开具(aRR 2.17;95%CI 1.92-2.46)均多于不筛查组。
- 筛查组警报发生率14.6%(4299/29442)低于不筛查组17.6%(5394/30613)。
- 筛查减少血管升压药治疗和多药耐药菌,但增加代码蓝色启动、新发肾脏替代治疗和艰难梭菌感染。
- 该试验在沙特阿拉伯5家医院病房开展,采用基于qSOFA的电子警报,从静默模式转为揭示模式实施筛查。
适用人群与场景
- 沙特阿拉伯5家医院45个病房收治的住院患者,共60055例,筛查组29442例、不筛查组30613例;中位年龄59岁(IQR 39-68),男性30596例(51.0%)。
- 研究场景为医院病房,非急诊或ICU;干预为病房层面的电子脓毒症筛查。
诊断标准与关键阈值
- 电子警报基于快速序贯器官衰竭评估(qSOFA)评分,在电子病历中以静默模式运行,筛查时激活为揭示模式。
处置流程与药物剂量
- 电子脓毒症筛查通过电子病历中的qSOFA警报从静默模式转为揭示模式实施;警报后12小时内筛查组血清乳酸检测(aRR 1.30;95%CI 1.16-1.45)和静脉液体开具(aRR 2.17;95%CI 1.92-2.46)多于不筛查组。
研究设计与关键结果
- 研究类型:阶梯楔形整群随机试验,在沙特阿拉伯5家医院45个病房(整群)开展,随机分为9个序列、每序列5个病房,每2个月实施筛查;研究时间2019年10月1日至2021年7月31日,随访至2021年10月29日。
- 人群:共60055例住院患者,筛查组29442例、不筛查组30613例;中位年龄59岁(IQR 39-68),男性30596例(51.0%)。
- 干预与对照:基于qSOFA的电子警报在电子病历中以静默模式激活为揭示模式进行脓毒症筛查 vs 不筛查。
- 主要终点:90天住院死亡率,筛查组低于不筛查组(aRR 0.85;95%CI 0.77-0.93;P<.001)。
- 警报发生:筛查组4299/29442例(14.6%) vs 不筛查组5394/30613例(17.6%)。
- 警报后12小时内:血清乳酸检测aRR 1.30(95%CI 1.16-1.45),静脉液体开具aRR 2.17(95%CI 1.92-2.46),均为筛查组高于不筛查组。
- 次要终点:筛查减少血管升压药治疗和多药耐药菌,但增加代码蓝色启动、新发肾脏替代治疗和艰难梭菌感染。
证据类型、等级与局限
- 证据类型:阶梯楔形整群随机试验(RCT)。
- 试验注册:ClinicalTrials.gov Identifier: NCT04078594。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在住院病房,基于qSOFA的电子脓毒症筛查(从静默模式转为揭示模式)与不筛查相比降低90天住院死亡率(aRR 0.85;95%CI 0.77-0.93;P<.001),并增加警报后12小时内血清乳酸检测(aRR 1.30;95%CI 1.16-1.45)和静脉液体开具(aRR 2.17;95%CI 1.92-2.46)。
- 筛查减少血管升压药治疗和多药耐药菌,但增加代码蓝色启动、新发肾脏替代治疗和艰难梭菌感染,临床实施时需权衡这些后果。
- 该研究在沙特阿拉伯5家医院病房开展,适用人群为住院病房患者,不涉及急诊或ICU场景。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sepsis screening is recommended among hospitalized patients but is supported by limited evidence of effectiveness.
OBJECTIVE: To evaluate the effect of electronic sepsis screening, compared with no screening, on mortality among hospitalized ward patients.
DESIGN, SETTING, AND PARTICIPANTS: In a stepped-wedge, cluster randomized trial at 5 hospitals in Saudi Arabia, 45 wards (clusters) were randomized into 9 sequences, 5 wards each, to have sepsis screening implemented at 2-month periods. The study was conducted between October 1, 2019, and July 31, 2021, with follow-up through October 29, 2021.
INTERVENTION: An electronic alert, based on the quick Sequential Organ Failure Assessment score, was implemented in the electronic medical record in a silent mode that was activated to a revealed mode for sepsis screening.
MAIN OUTCOMES AND MEASURES: The primary outcome was 90-day in-hospital mortality. There were 11 secondary outcomes, including code blue activation, vasopressor therapy, incident kidney replacement therapy, multidrug-resistant organisms, and Clostridioides difficile.
RESULTS: Among 60 055 patients, 29 442 were in the screening group and 30 613 in the no screening group. They had a median age of 59 years (IQR, 39-68), and 30 596 were male (51.0%). Alerts occurred in 4299 of 29 442 patients (14.6%) in the screening group and 5394 of 30 613 (17.6%) in the no screening group. Within 12 hours of the alert, patients in the screening group were more likely to have serum lactate tested (adjusted relative risk [aRR], 1.30; 95% CI, 1.16-1.45) and intravenous fluid ordered (aRR, 2.17; 95% CI, 1.92-2.46) compared with those in the no screening group. In the primary outcome analysis, electronic screening resulted in lower 90-day in-hospital mortality (aRR, 0.85; 95% CI, 0.77-0.93; P < .001). Screening reduced vasopressor therapy and multidrug-resistant organisms but increased code blue activation, incident kidney replacement therapy, and C difficile.
CONCLUSIONS AND RELEVANCE: Among hospitalized ward patients, electronic sepsis screening compared with no screening resulted in significantly lower in-hospital 90-day mortality.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04078594.
参考来源
- Arabi YM, Alsaawi A, Alzahrani M, et al. Electronic Sepsis Screening Among Patients Admitted to Hospital Wards: A Stepped-Wedge Cluster Randomized Trial. JAMA. 2025. PMID: 39658862. doi:10.1001/jama.2024.25982
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。